ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TRXB / insiders
AGMB (45) TECX (30) ZURA (29) PROK (35) ⌘ Pro Terminal →

TRex Bio Inc. (TRXB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$13.64 -0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.60

TRex Bio Inc. (TRXB) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $377.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TRXB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TRXB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, TRex Bio Inc. (NASDAQ: TRXB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.64 (-0.73% 1D, market cap $377.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TRXB ranks #288 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TRXB compare to AGMB and TECX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TRXB carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGMB (AgomAb Therapeutics NV) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $368.9M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, TRXB leads on earnings multiple (N/A) while TECX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TRXB?
▼

For TRex Bio Inc. (TRXB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #288 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.60 (-0.32%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (6)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$17 Bull$13 Base$10 Bear
📬 FREE TRXB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRXB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY TRXB SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($10.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$13.60+6.2% Next Q
Q2 (-2Q)
43
Grade D$14.44-4.5% Next Q
Q3 (-1Q)
45
Grade D$13.79-1.1% Next Q
Current
48
Grade D$13.64-5.6% Hist 90D α
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TRXB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TRXB currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.18) and Max Pain ($14.32) forces dealer call-delta covering toward $17.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRXB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TRXB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TRXB Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TRXB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TRXB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRXB)

  • ✓Walkthrough of TRXB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TRXB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.57%📐 HORIZONTAL RANGE
2026-11-03O $13.47H $14.05L $13.33C $13.64VOL 52.9K
SUP: $13.08SMA50: $14.10
$16.80$15.80$14.80$13.79$12.79SUP $13.08$13.642026-10-092026-10-152026-10-212026-10-272026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRXB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRXB Butterfly Map → + Track TRXB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TRXB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRXB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TRXB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRXB)

Health Care Rank #288 of 1015 ⚔️ AGMB vs TRXB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRXB vs. AGMB, TECX, ZURA, PROK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, TRex Bio Inc. (TRXB) ranks #288 by composite RQD confidence (48/100, grade D) and #482 by equity capitalization ($377.1M). Within this direct 5-issuer industry benchmark cohort, TRXB leads on earnings valuation at N/A trailing P/E, while TECX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TRXB currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TRXB ACTIVE
TRex Bio Inc.
D 48/100 — — — -0.73% $377.1M Benchmark Subject
AGMB
AgomAb Therapeutics NV
D 45/100 — — — -10.28% $368.9M /agmb-vs-trxb →
TECX
Tectonic Therapeutic Inc.
E 30/100 — — -35.0% -4.04% $386.7M /tecx-vs-trxb →
ZURA
Zura Bio Limited (Class A)
E 29/100 — — -35.0% -2.47% $389.2M /zura-vs-trxb →
PROK
ProKidney Corp. (Class A)
D- 35/100 — — -35.0% -13.51% $391.6M /prok-vs-trxb →

2. TRXB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

TRex Bio Inc. (TRXB) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $377.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. TRXB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRXB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, TRex Bio Inc. (NASDAQ: TRXB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.64 (-0.73% 1D, market cap $377.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TRXB ranks #288 in composite RQD confidence.

How does TRXB compare to AGMB and TECX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TRXB carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGMB (AgomAb Therapeutics NV) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $368.9M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, TRXB leads on earnings multiple (N/A) while TECX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRXB?

For TRex Bio Inc. (TRXB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #288 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRXB trading relative to its 50-day, 200-day, and 52-week technical levels?

TRXB last traded at $13.64 (-0.73% on volume of 54,856 shares), positioning the stock -3.81% below its 50-day simple moving average ($14.18) and -1.30% below its 200-day simple moving average ($13.82). Across its 52-week range of $13.10 to $16.56, TRXB sits at the 15.6% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.93 to $15.35).

Direct Sub-Reports: TRXB RQD Cockpit TRXB 12M Forecast TRXB Earnings & Move TRXB Dividends & DRIP TRXB Insiders & 13F TRXB Whale Options TRXB Profit Sankey TRXB News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ SEC XBRL & RQD VERIFIED

TRXB — TRex Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

TRex Bio Inc. (TRXB) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $13.64 (-0.73% 1D, market capitalization $377.1M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

— The profile identifies TRex Bio Inc. As a NASDAQ-listed Health Care issuer in Biotechnology: Biological Products (No Diagnostic Substances) with a market capitalization of $0.4B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 48/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $13.10 – $16.56 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), TRXB carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can TRXB sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $16.56 52-week high?
  • Key Question #3: How sensitive is TRXB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TRXB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TRex Bio Inc. (TRXB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TRXB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TRXB Bull vs. Bear Conversation Board — What's Your Call at $13.64?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TRXB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TRXB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $17.60 (+29.0%)
📌 Pinned Debate

Balance sheet forensics are the relative strength, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 contributing 13 of 20 points

The street is overcomplicating TRex Bio Inc. (TRXB). Balance sheet forensics are the relative strength, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 contributing 13 of 20 points.. With an RQD score of 48/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $14.73.

SectorRotator 🐂 BULL

@MacroHawk_NYC Agree on the RQD 48/100 quality, though with 1.0 beta I'm scaling in with half-size at $13.64 and keeping dry powder in case we test $12.69.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $10.91 (-20.0%)
Spot @ $13.64

Zero ROIC and zero FCF yield leave the cash engine at 12 of 20 points, with whale flow at 6 of 20 signalling weak institutional convict

I respect the product at TRex Bio Inc., but the stock at $13.64 is a different story. Zero ROIC and zero FCF yield leave the cash engine at 12 of 20 points, with whale flow at 6 of 20 signalling weak institutional conviction.. FCF yield is 0.0% and RQD sits at 48/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%